Cytokinetics (NASDAQ:CYTK) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Cytokinetics (NASDAQ:CYTK) had its price objective upped by research analysts at Needham & Company LLC from $72.00 to $84.00 in a research note issued on Monday, Marketbeat Ratings reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Needham & Company LLC’s target price points to a potential upside of 32.72% from the stock’s previous close.

Other analysts have also recently issued reports about the stock. Citizens Jmp raised their price target on shares of Cytokinetics from $78.00 to $88.00 and gave the stock a “market outperform” rating in a report on Monday. Bank of America increased their target price on shares of Cytokinetics from $52.00 to $56.00 and gave the stock a “neutral” rating in a research report on Thursday, October 2nd. HC Wainwright boosted their price target on shares of Cytokinetics from $120.00 to $136.00 and gave the company a “buy” rating in a report on Monday. Evercore ISI upped their price target on shares of Cytokinetics from $60.00 to $80.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 3rd. Finally, B. Riley reissued a “buy” rating and set a $90.00 price objective (up previously from $80.00) on shares of Cytokinetics in a research report on Monday, November 10th. Fifteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Cytokinetics has a consensus rating of “Moderate Buy” and a consensus price target of $83.61.

Cytokinetics Stock Down 3.5%

CYTK opened at $63.29 on Monday. The firm has a market capitalization of $7.74 billion, a P/E ratio of -10.06 and a beta of 0.58. The stock has a fifty day moving average of $62.87 and a 200-day moving average of $49.10. Cytokinetics has a 12-month low of $29.31 and a 12-month high of $70.98.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, beating the consensus estimate of ($1.59) by $0.05. The business had revenue of $1.94 million for the quarter, compared to analyst estimates of $6.05 million. The firm’s quarterly revenue was up 318.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.36) earnings per share. On average, analysts expect that Cytokinetics will post -5.24 earnings per share for the current fiscal year.

Insider Activity at Cytokinetics

In related news, Director Wendell Wierenga sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $66.14, for a total value of $1,322,800.00. Following the transaction, the director directly owned 32,444 shares of the company’s stock, valued at approximately $2,145,846.16. This trade represents a 38.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Andrew Callos sold 52,486 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $65.95, for a total value of $3,461,451.70. Following the completion of the sale, the executive vice president owned 50,660 shares of the company’s stock, valued at approximately $3,341,027. This trade represents a 50.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 168,494 shares of company stock valued at $10,811,018. Insiders own 3.40% of the company’s stock.

Institutional Trading of Cytokinetics

A number of institutional investors and hedge funds have recently modified their holdings of CYTK. HighTower Advisors LLC boosted its holdings in shares of Cytokinetics by 21.8% during the 1st quarter. HighTower Advisors LLC now owns 11,352 shares of the biopharmaceutical company’s stock worth $456,000 after buying an additional 2,029 shares during the period. American Century Companies Inc. lifted its position in Cytokinetics by 1.3% during the 1st quarter. American Century Companies Inc. now owns 361,388 shares of the biopharmaceutical company’s stock worth $14,524,000 after acquiring an additional 4,812 shares during the last quarter. Capital Fund Management S.A. boosted its holdings in Cytokinetics by 36.6% during the first quarter. Capital Fund Management S.A. now owns 55,264 shares of the biopharmaceutical company’s stock valued at $2,221,000 after acquiring an additional 14,818 shares during the period. CW Advisors LLC bought a new stake in Cytokinetics during the first quarter valued at about $1,125,000. Finally, AlphaQuest LLC grew its position in shares of Cytokinetics by 485.4% in the first quarter. AlphaQuest LLC now owns 6,650 shares of the biopharmaceutical company’s stock valued at $267,000 after purchasing an additional 5,514 shares during the last quarter.

Key Stores Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: FDA approved Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy, turning Cytokinetics into a commercial-stage cardiology biotech and opening a new revenue runway — a primary driver behind the rally. Article Title
• Positive Sentiment: Multiple brokers lifted price targets and reiterated buy/outperform views (Barclays, Morgan Stanley, BofA, Needham, Citizens/JMP), signaling stronger analyst conviction on commercial prospects and supporting upside. Article Title
• Positive Sentiment: Unusually heavy call-option buying (about 5,619 calls, ~103% above typical daily volume) suggests traders are positioning for additional upside or near-term bullish moves. (Options volume report)
• Positive Sentiment: Analyst commentary highlights practical label advantages for MYQORZO vs. the incumbent (flexible dosing), and management targets substantial market share gains — commentary that supports a multi-quarter adoption story. Article Title
• Neutral Sentiment: Citizens maintained its Market Outperform rating on CYTK, which is supportive but not a new endorsement. Article Title
• Negative Sentiment: Insider selling: director Wendell Wierenga sold 20,000 shares at an average $66.14 (Dec. 22), trimming his stake ~38% — a potential short-term headwind or cautionary signal for some investors. SEC Filing

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.